Valneva SE (4VLA)

Overview

Valneva SE is a pioneering specialty vaccine company hinged on the development, manufacturing, and commercialization of vaccines for infectious diseases that present significant unmet medical needs. With its inception in 1998, the company has rooted itself firmly in Saint-Herblain, France, and spans a vast distribution network covering the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, other European countries, and beyond on an international scale. Leveraging strategic collaborations, such as with Pfizer, Inc. for Lyme disease vaccine co-development and commercialization, and Instituto Butantan for chikungunya vaccine endeavors, Valneva stands at the forefront of vaccine innovation and public health advancement.

Products and Services

• IXIARO

  An inactivated Vero cell culture-derived vaccine aimed at the active immunization against Japanese encephalitis, safeguarding individuals from this dangerous neurological infection.

• DUKORAL

  A unique oral vaccine formulated for the deterrent of diarrhea attributable to Vibrio cholera and/or heat-labile toxin-producing enterotoxigenic Escherichia coli, promoting gastrointestinal wellness.

• IXCHIQ

  A single-dose, live-attenuated vaccine designed to prevent diseases caused by the chikungunya virus, furnishing protection against this debilitating virus.

• VLA2001

  An inactivated whole-virus COVID-19 vaccine, providing a form of active immunization against COVID-19, contributing to the global efforts in pandemic control.

• VLA15

  A promising vaccine candidate currently in Phase III clinical trials, targeting Borrelia, the bacterium responsible for Lyme disease, reflecting Valneva's commitment to tackling tick-borne infections.

• VLA1553

  Another Phase III clinical trial candidate, focused on combating the chikungunya virus, highlighting Valneva's continuous efforts in addressing viral diseases through innovative vaccine development.

• VLA1554

  A vaccine candidate in the development stages aimed at human metapneumovirus, underscoring the company's dedication to expanding its vaccine portfolio to cover a wider range of infectious diseases.

• VLA2112

  This candidate targets the treatment of patients with Epstein-Barr virus, indicating Valneva's strategic move towards developing vaccines for highly prevalent but less addressed viral infections.